Quote | BriaCell Therapeutics Corp. Warrant (NASDAQ:BCTXW)
Last: | $0.2099 |
---|---|
Change Percent: | 15.17% |
Open: | $0.1633 |
Close: | $0.2099 |
High: | $0.2255 |
Low: | $0.1605 |
Volume: | 13,800 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | BriaCell Therapeutics Corp. Warrant (NASDAQ:BCTXW)
Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar studies 1, 2, 3 Significant reduction of “Eye-Bulging” metastatic breast cancer tumor was previously rep...
BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literature Bria-IMT™ PFS compares favorably to PFS of most recent treatment in 48% of Antibody-Drug Conjugate (ADC) resistant patients Therapy well-tolerate...
Message Board Posts | BriaCell Therapeutics Corp. Warrant (NASDAQ:BCTXW)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
BriaCell Therapeutics Corp. Warrant Company Name:
BCTXW Stock Symbol:
NASDAQ Market:
BriaCell Therapeutics Corp. Warrant Website:
Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar studies 1, 2, 3 Significant reduction of “Eye-Bulging” metastatic breast cancer tumor was previously rep...
BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literature Bria-IMT™ PFS compares favorably to PFS of most recent treatment in 48% of Antibody-Drug Conjugate (ADC) resistant patients Therapy well-tolerate...
PHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer car...